ISBER 2023 Annual Meeting

Empowering genomics and biomarker discovery with proteomics

ISBER 2023 Annual Meeting

Date: May 3 – 6, 2023

Location: Westin Seattle | Seattle, WA, USA

Booth: 307/309

For the first time, Olink will be exhibiting at the ISBER 2023 Annual Meeting, the largest global event for biobanking. This conference serves as a valuable opportunity to connect with biobankers from academia, industry, and pharma to share knowledge and implement best practices in the industry.

Visit us at Booth 307/309 to meet the Olink team and join us for our workshop we are hosting May 3^rd!

Workshop name: Empowering genomics and biomarker discovery with proteomics

Date: May 3, 2023

Time: 2:00 – 3:00 PM PDT

Location: Cascade Ballroom II

Description: As genetic information has become easier and cheaper to collect, investments in genomics have resulted in valuable data resources and well characterized sample repositories. Many groups are investing in proteomics to help unlock additional value from genetic resources. Join us for a discussion around how biomarker discovery is enabling advances in neurodegenerative disease through public-private partnership. We will also discuss the advances enabled by multiomics including genomics, proteomics, epigenetics and transcriptomics. The discussion will be moderated and followed by a Q&A session and opportunities to network.

Workshop Sessions:

Targeted Proteomics in Neurodegenerative Diseases to Identify Potential Biomarkers of Disease – Aparna Vasanthakumar, Ph.D.

Harnessing the Power of Multiomics from a Single Sample – Andrea O’Hara, Ph.D.

Lessons from Proteomics, Clinical and Genetic Data from >60,000 Participants in the UK Biobank Pharma Proteomics Project – Cindy Lawley, Ph.D.

Speakers

Aparna Vasanthakumar, Ph.D
Senior Principal Research Scientist – AbbVie Genome Research Center

Aparna Vasanthakumar is a Senior Principal Research Scientist in the Genomics Research Center in AbbVie, where she directs pharmacogenomic and exploratory genomic studies in the Neuroscience, Specialty Medicine and Virology spaces. She was the 2019 chair of the Alzheimer’s disease neuroimaging Initiative (ADNI) private partners Scientific Board (PPSB), which manages the companies and private institutions that provide advice from the industry scientific perspective on the ADNI consortium. She also leads the ADNI DNA methylation working group, a sub-team within the ADNI Genetics core, which has as its objective the longitudinal epigenetic analysis of ADNI subjects to identify novel biomarkers of Alzheimer’s disease progression. She also served as the Programing Chair in the International Society to Advance Alzheimer’s Research and Treatment (ISTAART) Alliance of Women Researchers (AWARE) Professional Interest Area from 2020-2022.

Andrea O’Hara, Ph.D
Technical Specialist | Azenta Life Sciences

Andrea O’Hara is a technical specialist at Azenta Life Sciences and has over 14 years of experience in next generation sequencing. She earned her PhD from the University of North Carolina at Chapel Hill in genetics and molecular biology and did her postdoctoral training at the National Institutes of Health.

Cindy Lawley, Ph.D
Technical Specialist | Azenta Life Sciences

Cindy spent 14 years at Illumina starting in 2004 after completing her PhD at UC San Diego. While at Illumina, she founded the Consortia program and helped build over 40 commercial and shared genotyping beadchips through customer partnership. These included the MEGA and GSA arrays that still drive Illumina revenue today. Cindy joined Olink to drive population health initiatives, working closely with the UK Biobank, FinnGen, SCALLOP and other large cohort studies.